Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

Quince Therapeutics ( QNCX ) is pursuing the treatment of ataxia-telangiectasia, a rare neurodegenerative disorder, which starts in early childhood. I have covered the company in the summer of 2024, and the stock has performedI am working in the financial sector. My areas of interest are technology, biotech, pharmaceutical companies, banks and a bit of shipping when an actionable trade passes on my radar.Analyst’s Disclosure: I/we have a beneficial long position in the shares of QNCX either through stock ow ...